10 results on '"Zhao, Heng"'
Search Results
2. Non-invasive lung cancer diagnosis and prognosis based on multi-analyte liquid biopsy
- Author
-
Chen, Kezhong, Sun, Jianlong, Zhao, Heng, Jiang, Ruijingfang, Zheng, Jianchao, Li, Zhilong, Peng, Jiaxi, Shen, Haifeng, Zhang, Kai, Zhao, Jin, Zhu, Shida, Wang, Yuying, Yang, Fan, and Wang, Jun
- Published
- 2021
- Full Text
- View/download PDF
3. Monitoring of circulating tumor DNA and its aberrant methylation in the surveillance of surgical lung Cancer patients: protocol for a prospective observational study
- Author
-
Kang, Guannan, Chen, Kezhong, Yang, Fan, Chuai, Shannon, Zhao, Heng, Zhang, Kai, Li, Bingsi, Zhang, Zhihong, and Wang, Jun
- Published
- 2019
- Full Text
- View/download PDF
4. Video‐assisted thoracoscopic surgery lobectomy might be a feasible alternative for surgically resectable pathological N2 non‐small cell lung cancer patients.
- Author
-
Zhao, Jinbo, Li, Weimiao, Wang, Meng, Liu, Lunxu, Fu, Xiangning, Li, Yin, Xu, Lin, Liu, Yang, Zhao, Heng, Hu, Jian, Liu, Deruo, Shen, Jianfei, Yang, Haiying, and Li, Xiaofei
- Subjects
LUNG cancer prognosis ,CANCER patients ,CONFIDENCE intervals ,LENGTH of stay in hospitals ,LUNG cancer ,PNEUMONECTOMY ,PROPORTIONAL hazards models ,RETROSPECTIVE studies ,DESCRIPTIVE statistics ,KAPLAN-Meier estimator ,SURGICAL blood loss ,TERTIARY care ,ODDS ratio ,THORACOTOMY ,VIDEO-assisted thoracic surgery - Abstract
Background: The majority of previous studies of the clinical outcome of video‐assisted thoracoscopic surgery (VATS) versus open lobectomy for pathological N2 non‐small cell lung cancer (pN2 NSCLC) have been single‐center experiences with small patient numbers. The aim of this study was therefore to investigate these procedures but in a large cohort of Chinese patients with pathological N2 NSCLC in real‐world conditions. Methods: Patients who underwent lobectomy for pN2 NSCLC by either VATS or thoracotomy were retrospectively reviewed from 10 tertiary hospitals between January 2014 and September 2017. Perioperative outcomes and overall survival of the patients were analyzed. Cox regression analysis was performed to identify potential prognostic factors. Propensity‐score analysis was performed to reduce cofounding biases and compare the clinical outcomes between both groups. Results: Among 2144 pN2 NSCLC, 1244 patients were managed by VATS and 900 by open procedure. A total of 305 (24.5%) and 344 patients died during VATS and the thoracotomy group during a median follow‐up of 16.7 and 15.6 months, respectively. VATS lobectomy patients had better overall survival when compared with those undergoing the open procedure (P < 0.0001). Multivariate COX regression analysis showed VATS lobectomy independently favored overall survival (HR = 0.75, 95% CI: 0.621–0.896, P = 0.0017). Better perioperative outcomes, including less blood loss, shorter drainage time and hospital stay, were also observed in patients undergoing VATS lobectomy (P < 0.05). After propensity‐score matching, 169 patients in each group were analyzed, and no survival difference were found between the two groups. Less blood loss was observed in the VATS group, but there was a longer operation time. Conclusions: VATS lobectomy might be a feasible alternative to conventional open surgery for resectable pN2 NSCLC. Key points: Significant findings of the study: VATS lobectomy has comparative OS in pN2 NSCLC versus open procedure in resectable patients.What this study adds: VATS lobectomy might be feasible for pN2 NSCLC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Comprehensive assessment of the association between DNA repair gene XRCC3 rs861539 C/T polymorphism and lung cancer risk
- Author
-
Zhao-heng Ding, Weiguo Xu, Hong-Wei Hua, Gang Ding, Hong-Xiang Liang, Yu-feng Ni, and Qian Huang
- Subjects
medicine.medical_specialty ,Lung Neoplasms ,DNA Repair ,Population ,Bioinformatics ,Polymorphism, Single Nucleotide ,Gastroenterology ,Risk Factors ,Internal medicine ,Genetic model ,Humans ,Medicine ,Genetic Predisposition to Disease ,education ,Lung cancer ,Genetic Association Studies ,education.field_of_study ,business.industry ,Case-control study ,General Medicine ,Odds ratio ,medicine.disease ,Lung cancer susceptibility ,Confidence interval ,DNA-Binding Proteins ,Case-Control Studies ,Meta-analysis ,business - Abstract
A few case-control studies were performed to assess the association between X-ray repair cross-complementing group 3 (XRCC3) rs861539 C/T polymorphism and lung cancer susceptibility, but no consistent finding was reported. In the present study, we performed a meta-analysis of 14 case-control studies with a total of 7,869 lung cancer cases and 10,778 controls to provide a comprehensive assessment of the association between XRCC3 rs861539 C/T polymorphism and lung cancer risk. Pooled odds ratios (ORs) and corresponding 95 % confidence intervals (95 % CIs) were calculated to assess the strength of the association. Overall, there was no significant association between XRCC3 rs861539 C/T polymorphism and lung cancer risk under all genetic models [OR (95 % CI) for T versus C, 1.00 (0.89-1.13), P = 0.99; OR (95 % CI) for TT versus CC, 1.07 (0.81-1.41), P = 0.62; OR (95 % CI) for TT/CT versus CC, 0.95 (0.84-1.07), P = 0.39; OR (95 % CI) for TT versus CT/CC, 1.10 (0.86-1.39), P = 0.62]. In the subgroup analyses of both Asians and Caucasians, there was still no significant association between XRCC3 rs861539 C/T polymorphism and lung cancer risk under all genetic models (All P values were more than 0.05). However, there was an obvious association between XRCC3 rs861539 C/T polymorphism and decreased risk of lung cancer in the subgroup analysis of the mixed population (All P values were less than 0.05). In addition, there was some risk of publication bias in the meta-analysis, and there was obvious discrepancy in the findings between studies with large sample size and studies with small sample size in the meta-analysis. The meta-analysis indicates that the association between XRCC3 rs861539 C/T polymorphism and lung cancer risk is still uncertain owing to the obvious discrepancy in the findings between studies with large sample size and studies with small sample size. More studies with large sample size are needed to further assess the association.
- Published
- 2013
6. Comprehensive analysis of differentially expressed long non-coding RNAs in non-small cell lung cancer.
- Author
-
Zhou, Wenyong, Liu, Tao, Saren, Gaowa, Liao, Li, Fang, Wentao, and Zhao, Heng
- Subjects
NON-small-cell lung carcinoma ,NON-coding RNA ,LUNG cancer ,PROTEIN-protein interactions - Abstract
Non-small cell lung cancer (NSCLC) is the primary subtype of lung cancer. Long non-coding RNAs (lncRNAs) have been reported to serve prominent roles in cancer progression. However, the expression patterns and potential roles of lncRNAs in NSCLC remain to be elucidated. In the present study, four public datasets were analyzed to identify differentially expressed lncRNAs (DElncs) in NSCLC. A further dataset, GSE19188, was analyzed to validate the findings. A total of 38 upregulated and 31 downregulated lncRNAs were identified in NSCLC, compared with samples from healthy controls. Among these, 12 lncRNAs were associated with the progression of NSCLC, and dysregulated between high grade (stage III and IV) and low grade (stage II) NSCLC samples. Moreover, dysregulation of lncRNA-SIGLEC17P, GGTA1P, A2M-AS1, LINC00938, GVINP1, LINC00667 and TMPO-AS1 was associated with overall survival time in patients with NSCLC. Co-expression analyses, combined with the construction of protein-protein interaction networks, were performed to reveal the potential roles of key lncRNAs in NSCLC. The present study revealed a series of lncRNAs involved in the progression of NSCLS, which may serve as novel biomarkers for the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
7. Liquid biopsy in newly diagnosed patients with locoregional (I-IIIA) non-small cell lung cancer.
- Author
-
Chen, Kezhong, Kang, Guannan, Zhao, Heng, Zhang, Kai, Zhang, Jian, Yang, Fan, and Wang, Jun
- Abstract
Introduction: Liquid biopsy is a promising method for the management of lung cancer, but previous studies focused mainly on patients with advanced-stage disease. As the methodology has progressed for the detection of circulating tumor DNA (ctDNA) and its aberrant methylation, researchers are gradually investigating the utility of liquid biopsy in early-stage patients. As a result, liquid biopsy has shown its potential for the application in patients with early- and locally advanced-stage non-small cell lung cancer (NSCLC). Areas covered: This review summarizes the utility of liquid biopsy in NSCLC and provide an outlook for future development. We focus on the role of ctDNA and its aberrant methylation in patients with stage IA to stageⅢA NSCLC, in the field of early detection and screening, perioperative management, and postoperative surveillance. Expert opinion: Liquid biopsy has shown the potential for clinical application of early-stage patients but has not been routinely applied yet. The utilization of liquid biopsy will be promoted by improved detection methods and data from well-designed clinical trials. With the development of precision medicine, liquid biopsy will likely play an increasingly important clinical role. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
8. Role of circulating tumor DNA in the management of early‐stage lung cancer.
- Author
-
Zhao, Heng, Chen, Ke‐Zhong, Hui, Ben‐Gang, Zhang, Kai, Yang, Fan, and Wang, Jun
- Subjects
- *
CANCER relapse , *LUNG tumors , *TREATMENT of lung tumors , *TUMOR classification , *GENOMICS , *EARLY detection of cancer , *DIAGNOSIS , *CANCER risk factors - Abstract
Lung cancer is one of the most common cancers and the predominant cause of cancer‐related death in the world. The low accuracy of early detection techniques and high risk of relapse greatly contribute to poor prognosis. An accurate clinical tool that can assist in diagnosis and surveillance is urgently needed. Circulating tumor DNA (ctDNA) is free DNA shed from tumor cells and isolated from peripheral blood. The genomic profiles of ctDNA have been shown to closely match those of the corresponding tumors. With the development of approaches with high sensitivity and specificity, ctDNA plays a vital role in the management of lung cancer as a result of its reproducible, non‐invasive, and easy‐to‐obtain characteristics. However, most previous studies have focused on advanced lung cancer. Few studies have investigated ctDNA in the early stages of the disease. In this review, we focus on ctDNA obtained from patients in the early stage of lung cancer, provide a summary of the related literature to date, and describe the main approaches to ctDNA and the clinical applications. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
9. Four Common Vascular Endothelial Growth Factor Polymorphisms (−2578C>A, −460C>T, +936C>T, and +405G>C) in Susceptibility to Lung Cancer: A Meta-Analysis.
- Author
-
Lin, Ling, Cao, Kejian, Chen, Wenhu, Pan, Xufeng, and Zhao, Heng
- Subjects
GENETIC polymorphisms ,DISEASE susceptibility ,LUNG cancer ,REGULATION of neovascularization ,SQUAMOUS cell carcinoma ,META-analysis - Abstract
Background and Objective: Vascular endothelial growth factor (VEGF) is one of the key initiators and regulators of angiogenesis and it plays a vital role in the onset and development of malignancy. The association between VEGF gene polymorphisms and lung cancer risk has been extensively studied in recent years, but currently available results remain controversial or ambiguous. The aim of this meta-analysis is to investigate the associations between four common VEGF polymorphisms (i.e., −2578C>A, −460C>T, +936C>T and +405C>G) and lung cancer risk. Methods: A comprehensive search was conducted to identify all eligible studies to estimate the association between VEGF polymorphisms and lung cancer risk. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate the strength of this association. Results: A total of 14 published case-control studies with 4,664 cases and 4,571 control subjects were identified. Our meta-analysis provides strong evidence that VEGF −2578C>A polymorphism is capable of increasing lung cancer susceptibility, especially among smokers and lung squamous cell carcinoma (SCC) patients. Additionally, for +936C>T polymorphism, increased lung cancer susceptibility was only observed among lung adenocarcinoma patients. In contrast, VEGF −460C>T polymorphism may be a protective factor among nonsmokers and SCC patients. Nevertheless, we did not find any association between +405C>G polymorphism and lung cancer risk, even when the groups were stratified by ethnicity, smoking status or histological type. Conclusion: This meta-analysis recommends more investigations into the relationship between −2578C>A and −460C>T lung cancer risks. More detailed and well-designed studies should be conducted to identify the causal variants and the underlying mechanisms of the possible associations. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
10. Clinical Outcomes of Thoracoscopic Lobectomy for Patients With Clinical N0 and Pathologic N2 Non-Small Cell Lung Cancer.
- Author
-
Zhong, Chenxi, Yao, Feng, and Zhao, Heng
- Subjects
THORACOSCOPY ,TEMPORAL lobectomy ,LUNG cancer ,COMPARATIVE studies ,PLEURA surgery ,HEALTH outcome assessment - Abstract
Background: We compared the surgical outcomes in patients with clinical N0 and pathologic N2 (cN0-pN2) non–small cell lung cancer (NSCLC) who underwent video-assisted thoracoscopic surgery (VATS) lobectomy and open thoracotomy to evaluate the role of VATS lobectomy for cN0-pN2 disease. Methods: Between March 2006 and August 2011, 1,456 patients with clinical N0 NSCLC disease underwent lobectomy with systematic node dissection (SND) at Shanghai Chest Hospital. Of those patients, 157 were shown to have cN0-pN2 NSCLC. Of those, 67 patients underwent VATS lobectomy, and 90 patients underwent open lobectomy. SND was performed in all 157 patients. Clinicopathologic factors, local recurrence rates, and survival rates were compared. Results: The two groups were similar in age, sex, and pulmonary function. The VATS approach was associated with significantly shorter chest tube duration and postoperative stay than was the thoracotomy approach. Operative mortality, morbidity, and recurrence did not differ between the two groups. There was no significant difference between the two types of operation in numbers of total lymph nodes removed (17.4 ± 6.1 in the VATS group vs 18.1 ± 7.2 in the open group, p = 0.78) and mediastinal lymph nodes removed (11.7 ± 5.6 in the VATS group vs 12.0 ± 5.1 in the open group, p = 0.84). Similarly, the two groups were not significantly different with regard to stations of total lymph nodes removed (7.6 ± 1.9 in the VATS group vs 7.8 ± 2.3 in the open group, p = 0.81) and mediastinal lymph nodes removed (4.5 ± 1.1 in the VATS group vs 4.7 ± 1.3 in the open group, p = 0.71). The rates of overall survival and disease-free 5-year survival were not significantly different between the two groups. Conclusions: The clinical outcomes of thoracoscopic lobectomy were comparable to those of thoracotomy for patients with cN0-pN2 NSCLC. Single-station N2 is a good prognostic factor for disease-free survival in these patients. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.